CORDIS
EU research results

CORDIS

English EN
European Clinical trials in Rare Sarcomas within an integrated translational trial network

European Clinical trials in Rare Sarcomas within an integrated translational trial network

Objective

Sarcomas are rare malignant tumors, with an overall incidence of 6/105/year. Bone and soft tissue connective tissue tumours encompass more than 50 different rare histotypes and more than 150 different molecular subtypes. The incidence of individual rare sarcomas subtypes is often less than 0.5/105/year. Given sarcoma rarity as a group, but even more as individual entities, few prospective clinical trials testing local or systemic treatments have been performed in specific subtypes of sarcomas. Clinical trials in specific histological and molecular subtypes of sarcoma can only be performed through integrated clinical networks, centres of clinical excellence, supported by translational analysis. The drive for EUROSARC comes from the fact that sarcomas should now receive treatment adapted to histological and molecular subtypes and are ideal models to develop rational oncogene-targeted therapies. Trials based on selected molecular subtypes should now represent the standard approach to delineate novel treatments in individual disease subsets. They are also potential proof of concepts for first-in-class targeted treatment. EUROSARC aims at validating 1) novel local and systemic treatment strategies in localized phase, and 2) innovative targeted therapies in advanced phase based on the scientific understanding of molecular alterations driving the tumours thereby developing paradigm changing clinical research. The consortium builds on the successful co-ordination of scientific excellence of Conticanet and EuroBoNeT FP6 NoEs, where most partners were involved. The objective will be achieved through the development and conduct of 9 (2“Soft tissues” + 7“Bones”, 9 phase I/II and III) investigator-driven clinical trials in rare histological and molecular subtypes of sarcoma, through the establishment of an integrated consortium, gathering representatives of most European sarcoma groups, SME, all with proven track records of scientific and clinical excellence.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITE LYON 1 CLAUDE BERNARD

Address

Boulevard Du 11 Novembre 1918 Num43
69622 Villeurbanne Cedex

France

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 680 563,28

Administrative Contact

Javier Olaiz (Dr.)

Participants (19)

Sort alphabetically

Sort by EU Contribution

Expand all

ACADEMISCH ZIEKENHUIS LEIDEN

Netherlands

EU Contribution

€ 642 715,56

INSTITUT GUSTAVE ROUSSY

France

EU Contribution

€ 206 424,74

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 785 640,81

FONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI

Italy

EU Contribution

€ 385 033,31

ISTITUTO ORTOPEDICO RIZZOLI

Italy

EU Contribution

€ 278 642,53

INSTITUT BERGONIE

France

EU Contribution

€ 430 629,36

AZIENDA UNITA LOCALE SOCIO SANITARIA N 2 MARCA TREVIGIANA

Italy

EU Contribution

€ 480 596,28

FUNDACION DE INVESTIGACION DEL CANCER DE LA UNIVERSIDAD DE SALAMANCA

Spain

EU Contribution

€ 74 844,16

MARIA SKLODOWSKA-CURIE MEMORIAL CANCER CENTER

Poland

EU Contribution

€ 179 654

RUPRECHT-KARLS-UNIVERSITAET HEIDELBERG

Germany

EU Contribution

€ 191 535,70

Hospital Universitario Son Espases

Spain

EU Contribution

€ 32 004

EUROPEAN ORGANISATION FOR RESEARCH AND TREATMENT OF CANCER AISBL

Belgium

EU Contribution

€ 616 906,67

SARCOMA PATIENTS EURONET EV

Germany

EU Contribution

€ 58 200

THE UNIVERSITY OF BIRMINGHAM

United Kingdom

EU Contribution

€ 27 912

OXFORD GENE TECHNOLOGY (OPERATIONS) Ltd

United Kingdom

EU Contribution

€ 217 788,19

LYON INGENIERIE PROJETS

France

EU Contribution

€ 286 000

FUNDACION DE LA SOCIEDAD ESPANOLA DE LA ONCOLOGIA MEDICA

Spain

EU Contribution

€ 221 787,53

SERVICIO ANDALUZ DE SALUD

Spain

EU Contribution

€ 119 999,60

WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER

Germany

EU Contribution

€ 36 954,28

Project information

Grant agreement ID: 278742

Status

Closed project

  • Start date

    1 December 2011

  • End date

    31 May 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 885 914,25

  • EU contribution

    € 5 953 832

Coordinated by:

UNIVERSITE LYON 1 CLAUDE BERNARD

France